AI PRICE FORECAST
A Stock Forecast & AI Price Prediction
Agilent Technologies · Healthcare · Diagnostics & Research
A live signal snapshot
Shares of A were last at $176.95, down 0.52% on the day, trading 3.3% below its 52-week high of $182.99 and 63.3% above its 52-week low of $108.35. Stock Pulse 247's AI model currently rates A a BUY, at 87% model confidence. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $183.08, a 3.5% move from the last price.
A's 14-day RSI is 54.8 — a neutral zone, with no decisive edge for bulls or bears. The MACD indicator trails its signal line, with a histogram of -0.43 pointing to selling pressure. The 50-day moving average ($167.46) sits 21.7% above the 200-day ($137.56) — a "golden cross" structure that typically supports the longer-term uptrend.
20 Wall Street analysts covering A put the average price target at $182.05 (range $155.00–$200.00), implying 2.9% upside from the current price. The current recommendation trend leans bullish: 15 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 7 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive A dashboard for numbers updated throughout today's session.
About Agilent Technologies
Agilent Technologies, Inc. (A) is a diagnostics & research company in the healthcare sector, headquartered in Santa Clara, CA, United States. Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It has a market value of about $49.9 billion and roughly 18,200 full-time employees. Its beta of 1.24 means it has historically moved roughly in line with the market.
A performance vs. the market
Year to date, A has gained 30.0%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 20.9%, 9.4 points better than the S&P 500. Its +3.1% move over the past month extends a +18.5% three-month run.
| Period | A | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +3.1% | +11.4% | −2.3% |
| 3 months | +18.5% | +12.2% | −2.3% |
| Year to date | +30.0% | +22.1% | +11.4% |
| 1 year | +20.9% | +28.3% | +11.5% |
Agilent Technologies financials at a glance
Agilent Technologies's most recent quarter (ended Jul 31, 2026) brought in $1.9 billion of revenue and net income of $362 million (a 19.3% net margin). Revenue was up 8.1% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 34.9 on trailing earnings of $5.07 per share. Trailing free cash flow was $1.1 billion, and total debt equals 56% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Jul 31, 2026 | $1.9B | $362M |
| Apr 30, 2026 | $1.8B | $339M |
| Jan 31, 2026 | $1.8B | $305M |
| Oct 31, 2025 | $1.9B | $434M |
A vs. its peers
A's +30.0% this year ranks ahead of 4 of the 5 big healthcare names below. The strongest of the group this year is Eli Lilly and (LLY, +33.7%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Agilent Technologies (A) | $176.95 | +30.0% | 34.9 | BUY |
| Thermo Fisher Scientific (TMO) | $717.71 | +23.9% | 37.9 | BUY |
| Danaher (DHR) | $235.31 | +2.8% | 39.0 | BUY |
| IDEXX Laboratories (IDXX) | $702.59 | +3.9% | 47.3 | BUY |
| IQVIA Holdings (IQV) | $274.53 | +21.8% | 33.4 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
A stock: common questions
What is the A stock price target?
20 Wall Street analysts put the average 12-month target at $182.05, in a range of $155.00–$200.00, versus a recent price of $176.95. Stock Pulse 247's model projects about $183.08 over the next month.
Is A a buy right now?
Our AI model currently rates A a BUY at 87% confidence. Among analysts, 15 rate it Buy or Strong Buy, 7 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has A stock performed this year?
Year to date, A has gained 30.0%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 20.9%, 9.4 points better than the S&P 500. Its +3.1% move over the past month extends a +18.5% three-month run.
What is A's 52-week high and low?
A has traded between $108.35 and $182.99 over the past 52 weeks; at $176.95 it is 3.3% below its 52-week high of $182.99 and 63.3% above its 52-week low of $108.35.
What sector is A in, and who are its peers?
A is in the healthcare sector (diagnostics & research). Its largest peers on Stock Pulse 247 include Thermo Fisher Scientific (TMO), Danaher (DHR), IDEXX Laboratories (IDXX), IQVIA Holdings (IQV).
How accurate is the A forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines A's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.